Epidermal Growth Factor Receptor (EGFR)-targeted therapies in esophagogastric cancer

Anticancer Research

Volumn 33, Issue 10, 2013, Pages 4139-4156

  Ayyappan, Sabarish ^a   Prabhakar, Dhivya ^a   Sharma, Neelesh ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Cetuximab; EGFR; Esophageal cancer; Gastric cancer; Review; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4;

CANCER FAMILY; CANCER THERAPY; DRUG MECHANISM; ESOPHAGOGASTRIC CANCER; ESOPHAGUS CANCER; GENE EXPRESSION; GENE MUTATION; HUMAN; ONCOGENE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STOMACH CANCER;

CETUXIMAB; EGFR; ESOPHAGEAL CANCER; GASTRIC CANCER; REVIEW; TRASTUZUMAB;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84891361354     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (166)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer 2010.
2. Blot WJ and McLaughlin JK: The changing epidemiology of esophageal cancer. Semin Oncol 26: 2-8, 1999.
3. Keeney S BT: Epidemiology of adenocarcinoma of the esophagogastric junction. Surg Oncol Clin N Am 15: 687, 2006.
4. Wilkinson N, Howe J, Gay G, Patel-Parekh L, Scott-Conner C and Donohue J: Differences in the Pattern of Presentation and Treatment of Proximal and Distal Gastric Cancer: Results of the 2001 Gastric Patient Care Evaluation. Annals of Surgical Oncology 15: 1644-1650, 2008.
5. Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK and Fraumeni JF Jr.: The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 274: 474-477, 1995.
6. Heath EI, Limburg PJ, Hawk ET and Forastiere AA: Adenocarcinoma of the esophagus: risk factors and prevention. Oncology (Williston Park, NY) 14: 507-514; discussion 518-520, 522-503, 2000.
7. Lagergren J, Bergstrom R and Nyren O: Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Annals of internal medicine 130: 883-890, 1999.
8. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT and Funch-Jensen P: Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 365: 1375-1383, 2011.
9. Enzinger PC and Mayer RJ: Esophageal Cancer. N Engl J Med 349: 2241-2252, 2003.
10. Cunningham D, Okines AF and Ashley S: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 362: 858-859, 2010.
11. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse M-L and Ajani JA: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group. J Clin Oncol 24: 4991-4997, 2006.
12. Franklin WA, Veve R, Hirsch FR, Helfrich BA and Bunn PA Jr.: Epidermal growth factor receptor family in lung cancer and premalignancy. Seminars in Oncology 29: 3-14, 2002.
13. Salomon DS, Brandt R, Ciardiello F and Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology/ Hematology 19: 183-232, 1995.
14. Marshall J: Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107: 1207-1218, 2006.
15. Brand TM, Iida M and Wheeler DL: Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biology & Therapy 11: 777-792, 2011.
16. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L and Hung MC: Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3: 802-808, 2001.
17. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, Bartholomeusz G, Shih JY and Hung MC: Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7: 575-589, 2005.
18. Lo HW, Cao X, Zhu H and Ali-Osman F: Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Mol Cancer Res 8: 232-245, 2010.
19. Hung LY, Tseng JT, Lee YC, Xia W, Wang YN, Wu ML, Chuang YH, Lai CH and Chang WC: Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression. Nucleic Acids Res 36: 4337-4351, 2008.
20. Hanada N, Lo HW, Day CP, Pan Y, Nakajima Y and Hung MC: Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol Carcinog 45: 10-17, 2006.
21. Graus-Porta D, Beerli RR, Daly JM and Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16: 1647-1655, 1997.
22. Wang LM, Kuo A, Alimandi M, Veri MC, Lee CC, Kapoor V, Ellmore N, Chen XH and Pierce JH: ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. Proceedings of the National Academy of Sciences of the United States of America 95: 6809-6814, 1998.
23. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M and Yarden Y: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15: 2452-2467, 1996.
24. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N and Ooi A: EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. International journal of cancer Journal international du cancer 118: 1173-1180, 2006.
25. Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, Bessaguet C, Lagarde N and Volant A: Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 93: 107-115, 2005.
26. Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A and Albarracin CT: Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 109: 658-667, 2007.
27. Cronin J, McAdam E, Danikas A, Tselepis C, Griffiths P, Baxter J, Thomas L, Manson J and Jenkins G: Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE). The American journal of gastroenterology 106: 46-56, 2011.
28. Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, Pinto M, Zamboli A, De Vita F and Ferraraccio F: Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World journal of surgery 31: 1458-1468, 2007.
29. Wang YK, Gao CF, Yun T, Chen Z, Zhang XW, Lv XX, Meng NL and Zhao WZ: Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization. Molecular cytogenetics 4: 14, 2011.
30. Bang Y, Chung H, Xu J, Lordick F, Sawaki A, Al-Sakaff N, Lipatov O, See C, Rueschoff J and Van Cutsem E: Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. ASCO Meeting Abstracts 27: 4556, 2009.
31. Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M and Viale G: HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012.
32. Ruschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Hofler H and Kreipe HH: HER2 diagnostics in gastric cancerguideline validation and development of standardized immunohistochemical testing. Virchows Archiv: an international journal of pathology 457: 299-307, 2010.
33. Dahlberg PS, Jacobson BA, Dahal G, Fink JM, Kratzke RA, Maddaus MA and Ferrin LJ: ERBB2 amplifications in esophageal adenocarcinoma. The Annals of thoracic surgery 78: 1790-1800, 2004.
34. Friess H, Fukuda A, Tang WH, Eichenberger A, Furlan N, Zimmermann A, Korc M and Buchler MW: Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World journal of surgery 23: 1010-1018, 1999.
35. Yoshida K, Kuniyasu H, Yasui W, Kitadai Y, Toge T and Tahara E: Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha. Journal of cancer research and clinical oncology 119: 401-407, 1993.
36. Phillips BE, Tubbs RR, Rice TW, Rybicki LA, Plesec T, Rodriguez CP, Videtic GM, Saxton JP, Ives DI and Adelstein DJ: Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction. Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus/ISDE 2012.
37. Cho H-S, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW and Leahy DJ: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760, 2003.
38. Clynes RA, Towers TL, Presta LG and Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Medicine 6: 443-446, 2000.
39. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Prada GD, Zambelli A and Costa A: Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2. Clinical Cancer Research 10: 5650-5655, 2004.
40. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J and Baselga J: Trastuzumab (Herceptin), a Humanized Anti-HER2 Receptor Monoclonal Antibody, Inhibits Basal and Activated HER2 Ectodomain Cleavage in Breast Cancer Cells. Cancer Res 61: 4744-4749, 2001.
41. Nagata Y, Lan KH, Zhou XY, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC and Yu DH: PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127, 2004.
42. Kos KS, Zhou XY, Lee S, Zhang LL, Yang WT, Nagata Y and Yu DH: Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 98: 1377-1385, 2003.
43. Lane HA, Motoyama AB, Beuvink I and Hynes NE: Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Annals of Oncology 12: S21-S22, 2001.
44. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD and Herceptin Adjuvant Trial Study T: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. The New England journal of medicine 353: 1659-1672, 2005.
45. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ and team Hs: 2- year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369: 29-36, 2007.
46. Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J and Kang Y-K: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet 376: 687-697.
47. Safran H, Dipetrillo T, Akerman P, Ng T, Evans D, Steinhoff M, Benton D, Purviance J, Goldstein L, Tantravahi U and Kennedy T: Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 67: 405-409, 2007.
48. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RVJ, Lutz RJ, Wong WLT, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD and Sliwkowski MX: Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate. Cancer research 68: 9280-9290, 2008.
49. Barok M, Tanner M, Koninki K and Isola J: Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer letters 306: 171-179, 2011.
50. Goldstein NI, Prewett M, Zuklys K, Rockwell P and Mendelsohn J: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clinical cancer research: an official journal of the American Association for Cancer Research 1: 1311-1318, 1995.
51. Waksal HW: Role of an anti-epidermal growth factor receptor in treating cancer. Cancer metastasis reviews 18: 427-436, 1999.
52. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ and Zalcberg JR: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England journal of medicine 359: 1757-1765, 2008.
53. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK and Ang KK: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The lancet oncology 11: 21-28, 2010.
54. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A and Baselga J: Openlabel, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 25: 2171-2177, 2007.
55. Patel D, Bassi R, Hooper A, Prewett M, Hicklin DJ and Kang X: Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. International journal of oncology 34: 25-32, 2009.
56. Zhang J, Ji J, Yuan F, Ma T, Ye ZB, Yu YY, Liu BY and Zhu ZG: EGFR-blockade by antibody Cetuximab inhibits the growth of human gastric cancer xenograft in nude mice and its possible mechanism. Zhonghua zhong liu za zhi [Chinese journal of oncology] 31: 85-89, 2009.
57. Enzinger PC, Burtness B, Hollis D, Niedzwiecki D, Ilson D, Benson AB, Mayer RJ and Goldberg RM: CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. ASCO Meeting Abstracts 28: 4006, 2010.
58. Lorenzen S, Schuster T, Porschen R, Al-Batran S-E, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, Müller L, Röthling N, Peschel C, Langer R and Lordick F: Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5- fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Annals of Oncology 20: 1667-1673, 2009.
59. Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Woll E, Decker T, Endlicher E, Rothling N, Schuster T, Keller G, Fend F and Peschel C: Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 102: 500-505, 2010.
60. Yeh K, Hsu C, Hsu C, Lin C, Shen Y, Wu S, Chiou T, Chao Y and Cheng A: Phase II study of cetuximab plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for the first-line treatment of advanced gastric cancer. ASCO Meeting Abstracts 27: 4567, 2009.
61. Kim C, Lee JL, Ryu MH, Chang HM, Kim TW, Lim HY, Kang HJ, Park YS, Ryoo BY and Kang YK: A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Investigational new drugs 29: 366-373, 2011.
62. Schonnemann KR, Yilmaz M, Bjerregaard JK, Nielsen KM and Pfeiffer P: Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer. Eur J Cancer 48: 510-517, 2012.
63. Park SR, Kook MC, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim YW, Ryu KW, Lee JH, Lee JS, Park YI and Kim NK: Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients. Cancer chemotherapy and pharmacology 65: 579-587, 2010.
64. Ku GY, Shah MA, Tang LH, Miron B, Kelsen DP and Ilson DH: Cetuximab (C225) plus irinotecan/cisplatin (CPT/Cis) for CPT/Cis-refractory esophageal cancer. ASCO Meeting Abstracts 26: 15580, 2008.
65. Schønnemann KR, Yilmaz M, Bjerregaard JK, Nielsen KM and Pfeiffer P: Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer. Eur J Cancer 2012.
66. Li J, Liu X, Wang BY, Guo WJ, Yin JL, Zhu XD, Zhang J and Liu T: Phase II study of cetuximab in combination with modified FOLFIRI in patients with advanced gastric cancer who failed firstline chemotherapy (EFFI study). ASCO Meeting Abstracts 28: 4107, 2010.
67. Gold PJ, Goldman B, Iqbal S, Leichman LP, Lenz HJ and Blanke CD: Cetuximab as second-line therapy in patients with metastatic esophageal cancer: A phase II Southwest Oncology Group Study. ASCO Meeting Abstracts 26: 4536, 2008.
68. Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E and Fuchs CS: A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 22: 1367-1373, 2011.
69. Lee MS, Mamon HJ, Hong TS, Choi NC, Fidias PM, Kwak EL, Meyerhardt JA, Ryan DP, Bueno R, Donahue DM, Jaklitsch MT, Lanuti M, Rattner DW, Fuchs CS and Enzinger PC: Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. The oncologist 18: 281- 287, 2013.
70. Safran H, Suntharalingam M, Dipetrillo T, Ng T, Doyle LA, Krasna M, Plette A, Evans D, Wanebo H, Akerman P, Spector J, Kennedy N and Kennedy T: Cetuximab With Concurrent Chemoradiation for Esophagogastric Cancer: Assessment of Toxicity. International Journal of Radiation Oncology* Biology*Physics 70: 391-395, 2008.
71. Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, von Moos R, Moosmann P, Montemurro M, Schneider PM, Rauch D, Gautschi O, Mingrone W, Widmer L, Inauen R, Brauchli P and Hess V: Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06). Journal of Clinical Oncology 29: 626-631, 2011.
72. De Vita F, Orditura M, Innocente R, Vecchione L, Pinto C, Chiarion Sileni V, Martinelli E, Ruol A, Catalano G and Ciardiello F: A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC). ASCO Meeting Abstracts 27: 4546, 2009.
73. De Vita F, Orditura M, Martinelli E, Vecchione L, Innocenti R, Sileni VC, Pinto C, Di Maio M, Farella A, Troiani T, Morgillo F, Napolitano V, Ancona E, Di Martino N, Ruol A, Galizia G, Del Genio A and Ciardiello F: A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br J Cancer 104: 427-432, 2011.
74. Tomblyn MB, Goldman BH, Thomas CR Jr., Benedetti JK, Lenz HJ, Mehta V, Beeker T, Gold PJ, Abbruzzese JL and Blanke CD: Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 7: 906-912, 2012.
75. Chen Y, Wu X, Bu S, He C, Wang W, Liu J, Guo W, Tan B, Wang Y and Wang J: Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma. Cancer Sci 103: 1979-1984, 2012.
76. Rao S, Starling N, Cunningham D, Sumpter K, Gilligan D, Ruhstaller T, Valladares-Ayerbes M, Wilke H, Archer C, Kurek R, Beadman C and Oates J: Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Annals of Oncology 21: 2213-2219, 2010.
77. Grothey A: EGFR Antibodies in Colorectal Cancer: Where Do They Belong? Journal of Clinical Oncology 28: 4668-4670, 2010.
78. Okines AF, Ashley SE, Cunningham D, Oates J, Turner A, Webb J, Saffery C, Chua YJ and Chau I: Epirubicin, oxaliplatin and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 28: 3945-3950, 2010.
79. Waddell T, Chau I, Cunningham D, Gonzalez D, Frances A, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C and Barbachano Y: Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. The lancet oncology 14: 481-489, 2013.
80. Waddell TS, Chau I, Barbachano Y, Gonzalez de Castro D, Wotherspoon A, Saffery C, Middleton GW, Wadsley J, Ferry DR, Mansoor W, Crosby TDL, Coxon FY, Smith D, Waters JS, Iveson T, Falk S, Slater S, Okines AFC and Cunningham D: A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). ASCO Meeting Abstracts 30: LBA4000, 2012.
81. Okines AF, Gonzalez de Castro D, Cunningham D, Chau I, Langley RE, Thompson LC, Stenning SP, Saffery C, Barbachano Y, Coxon F, Middleton G, Ferry D, Crosby T, Madhusudan S, Wadsley J, Waters J, Hall M, Swinson D, Robinson A, Smith D, Reis-Filho JS, Waddell TS, Puckey L, Hulkki Wilson S, Eltahir Z, Band M and Wotherspoon A: Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials. Eur J Cancer 2013.
82. Allan DG: Nimotuzumab: evidence of clinical benefit without rash. The oncologist 10: 760-761, 2005.
83. Ling Y, Chen J, Tao M, Chu X and Zhang X: A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma. Journal of thoracic disease 4: 58-62, 2012.
84. Chi Y, Zheng Z, Zhou A, Yang L, Qu T, Jiang W, Shi S, Sun Y, Song Y, Kang S and Wang J: Randomized, single-centered, phase II clinical trial of nimotuzumab plus cisplatin and S-1 as first-line therapy in patients with advanced gastric cancer. ASCO Meeting Abstracts 29: e21021, 2011.
85. Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, Perez ML, Soriano JL, Gonzalez CE, Hernadez IM, Albuerne YA, Moreno BP, Alvarez ES, Callejo IP, Alert J, Martell JA, Gonzalez YS, Gonzalez YS, Astudillo de la Vega H, Ruiz-Garcia EB and Ramos TC: Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer biology & therapy 13: 600-605, 2012.
86. Zhang X, Lu M, Wang X, Li J, Li Y, Li J, Zhang X, Gao J, Zhou J, Lu Z, Gong J, Jia J, Cui Y, Yu J and Shen L: Nimotuzumab plus paclitaxel and cisplatin as first-line treatment for esophageal squamous cell cancer: A single center prospective clinical trial. ASCO Meeting Abstracts 31: 4097, 2013.
87. Wang J-W, Chi Y, Zheng Z-x, Qu T, Zhou A-P, Yang L, Jiang Wc, Shi S-z, Sun Y-k, Song Y and Kang S-y: Randomized, singlecentered, phase II clinical trial of nimotuzumab plus cisplatin and S-1 as first-line therapy in patients with advanced gastric cancer. ASCO Meeting Abstracts 30: e14668, 2012.
88. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM and Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer cell 5(4): 317-328, 2004.
89. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J and Hasmann M: Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models. Cancer research 69: 9330-9336, 2009.
90. Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M and Fujimoto-Ouchi K: Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models. Clinical Cancer Research 17: 5060-5070, 2011.
91. Mendelsohn J: Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clinical Cancer Research 3: 2703-2707, 1997.
92. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L and National Cancer Institute of Canada Clinical Trials G: Erlotinib in previously treated non-small-cell lung cancer. The New England journal of medicine 353: 123-132, 2005.
93. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W and National Cancer Institute of Canada Clinical Trials G: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 25: 1960-1966, 2007.
94. Rodriguez CP, Adelstein DJ, Rybicki LA, Rice TW, Videtic GM, Saxton JP, Murthy SC, Mason DP and Ives DI: A phase II trial of perioperative concurrent chemoradiotherapy (CCRT) and gefitinib (G) in locally advanced esophagus (E) and gastroesophageal junction (GEJ) cancer. ASCO Meeting Abstracts 26: 4547, 2008.
95. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, Van Groeningen C and Giaccone G: Predictive Factors for Outcome in a Phase II Study of Gefitinib in Second-Line Treatment of Advanced Esophageal Cancer Patients. Journal of Clinical Oncology 24: 1612-1619, 2006.
96. Adelstein DJ, Rodriguez CP, Rybicki LA, Ives DI and Rice TW: A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. Investigational new drugs 2011.
97. Li G, Hu W, Wang J, Deng X, Zhang P, Zhang X, Xie C and Wu S: Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma. Int J Radiat Oncol Biol Phys 78: 1407-1412, 2010.
98. Wainberg ZA, Lin LS, DiCarlo B, Dao KM, Patel R, Park DJ, Wang HJ, Elashoff R, Ryba N and Hecht JR: Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastrooesophageal junction. British journal of cancer 105: 760-765, 2011.
99. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD and Abbruzzese JL: Phase II Trial of Erlotinib in Gastroesophageal Junction and Gastric Adenocarcinomas: SWOG 0127. Journal of Clinical Oncology 24: 4922-4927, 2006.
100. Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, Treece AL, Hardwicke MA, Dush M, Liao Q, Westlund RE, Zhao S, Bacus S and Spector NL: Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer research 66: 1640-1647, 2006.
101. Xia W, Gerard CM, Liu L, Baudson NM, Ory TL and Spector NL: Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24: 6213-6221, 2005.
102. Kim JW, Kim HP, Im SA, Kang S, Hur HS, Yoon YK, Oh DY, Kim JH, Lee DS, Kim TY and Bang YJ: The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer letters 272: 296-306, 2008.
103. Wainberg ZA: Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 16: 1509-1519, 2010.
104. Iqbal S, Goldman B, Lenz HJ, Fenoglio-Preiser CM and Blanke CD: S0413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer. ASCO Meeting Abstracts 25: 4621, 2007.
105. Galsky MD, Von Hoff DD, Neubauer M, Anderson T, Fleming M, Sweetman RW, Mahoney J, Midwinter D, Vocila L and Zaks TZ: Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. ASCO Meeting Abstracts 27: 3541, 2009.
106. Hecht JR, Bang Y-J, Qin S, Chung H-C, Xu J-M, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero AF, Salman P, Li J, Protsenko S, Buyse ME, Afenjar K, Kaneko T, Kemner A, Santillana S, Press MF and Slamon DJ: Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. ASCO Meeting Abstracts 31: LBA4001, 2013.
107. Oh D-Y, Lee K-W, Cho JY, Kang WK, Rha SY and Bang Y-J: A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen. ASCO Meeting Abstracts 30: 54, 2012.
108. Hsieh AC and Moasser MM: Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 97: 453-457, 2007.
109. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, 3rd and Hynes NE: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proceedings of the National Academy of Sciences of the United States of America 100: 8933-8938, 2003.
110. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, Wang S, Garcia-Echeverria C and Maira SM: Specific apoptosis induction by the dual PI3K/mTor inhibitor NVPBEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 106: 22299-22304, 2009.
111. Hayashi M, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T and Sugihara K: High Expression of HER3 Is Associated with a Decreased Survival in Gastric Cancer. Clinical Cancer Research 14: 7843-7849, 2008.
112. Feng SM, Sartor CI, Hunter D, Zhou H, Yang X, Caskey LS, Dy R, Muraoka-Cook RS and Earp HS, 3rd: The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation. Molecular endocrinology (Baltimore, Md) 21: 1861- 1876, 2007.
113. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England journal of medicine 351: 337-345, 2004.
114. Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S, Hermann RC, Lynch TJ and Weber MR: Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. Journal of clinical
115. Sartore-Bianchi A, Bencardino K, Cassingena A, Venturini F, Funaioli C, Cipani T, Amatu A, Pietrogiovanna L, Schiavo R, Di Nicolantonio F, Artale S, Bardelli A and Siena S: Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. Cancer Treatment Reviews 36(Suppl 3): S1-S5, 2010.
116. Lordick F, Lorenzen S, Hegewisch-Becker S, Folprecht G, Woll E, Decker T, Endlicher E, Rothling N, Fend F and Peschel C: Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group. ASCO Meeting Abstracts 25: 4526, 2007.
117. Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G, Artale S, Mutri V, Giaquinta S, Giannetta L, Bardelli A and Martoni AA: Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 101: 1261-1268, 2009.
118. Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR, Kanzler S and German Arbeitsgemeinschaft Internistische O: Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 22: 1358-1366, 2011.
119. Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ and Kim TY: Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 100: 298-304, 2009.
120. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent- Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M and Tejpar S: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. The lancet oncology 11: 753-762, 2010.
121. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF and Schilsky RL: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27: 2091-2096, 2009.
122. Bardelli A and Siena S: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 28: 1254-1261, 2010.
123. Lee SH, Lee JW, Soung YH, Kim HS, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Nam SW, Kim SH, Lee JY and Yoo NJ: BRAF and KRAS mutations in stomach cancer. Oncogene 22: 6942-6945, 2003.
124. Kim IJ, Park JH, Kang HC, Shin Y, Park HW, Park HR, Ku JL, Lim SB and Park JG: Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Human genetics 114: 118-120, 2003.
125. Nanus DM, Kelsen DP, Mentle IR, Altorki N and Albino AP: Infrequent point mutations of ras oncogenes in gastric cancers. Gastroenterology 98: 955-960, 1990.
126. Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, Espin E, Armengol M, Yamamoto H, Hamelin R, Seruca R and Schwartz S Jr.: BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 22: 9192-9196, 2003.
127. Stella G: KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients [abstract]. J Clin Oncol 27: a15503, 2009.
128. Esteva FJ, Yu D, Hung MC and Hortobagyi GN: Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nature reviews Clinical oncology 7: 98-107, 2010.
129. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC and Yu D: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer cell 6: 117-127, 2004.
130. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe F, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E and Martoni A: Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Annals of Oncology 18: 510-517, 2007.
131. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR and Tortora G: Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy. Clinical Cancer Research 10: 784-793, 2004.
132. Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S, Tarallo V, De Falco S, Melisi D, Benelli R, Albini A, Ryan A, Ciardiello F and Tortora G: Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells. Clinical Cancer Research 14: 5069-5080, 2008.
133. Heindl S, Eggenstein E, Keller S, Kneissl J, Keller G, Mutze K, Rauser S, Gasteiger G, Drexler I, Hapfelmeier A, Hofler H and Luber B: Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines. Journal of cancer research and clinical oncology 2012.
134. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT and Harari PM: Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27: 3944-3956, 2008.
135. Li C, Iida M, Dunn EF, Ghia AJ and Wheeler DL: Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28: 3801-3813, 2009.
136. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E and Ciardiello F: Implications for KRAS status and EGFRtargeted therapies in metastatic CRC. Nature reviews Clinical oncology 6: 519-527, 2009.
137. Nahta R, Yuan LXH, Zhang B, Kobayashi R and Esteva FJ: Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells. Cancer research 65: 11118- 11128, 2005.
138. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE and Park BH: The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biology & Therapy 3: 772-775, 2004.
139. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian Y-W, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MHT, Blanchard KL and Thomas JE: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439-444, 2007.
140. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She Q-B, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L, Isola J, Bendahl P-O, Rosen N, Hibshoosh H, Ringnér M, Borg Å and Parsons R: Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proceedings of the National Academy of Sciences 104: 7564-7569, 2007.
141. Itakura Y, Sasano H, Shiga C, Furukawa Y, Shiga K, Mori S and Nagura H: Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 74: 795-804, 1994.
142. Reichelt U, Duesedau P, Tsourlakis M, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R, Izbicki JR and Sauter G: Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 20: 120-129, 2007.
143. Hardwick RH, Barham CP, Ozua P, Newcomb PV, Savage P, Powell R, Rahamin J and Alderson D: Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 23: 30-35, 1997.
144. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, Ooi A and Fujii H: Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 92: 1253-1260, 2005.
145. Rossi E, Villanacci V, Bassotti G, Casa DD, Missale G, Minelli L and Cestari R: Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization. Diagnostic molecular pathology: the American journal of surgical pathology, part B 15: 125-130, 2006.
146. Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, Fujino MA and Ooi A: Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immunosorbent assay. International journal of cancer Journal international du cancer 98: 833-837, 2002.
147. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K and Isola J: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 16: 273-278, 2005.
148. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH and Sepulveda AR: HER-2/neu amplification is an independent prognostic factor in gastric cancer. Digestive diseases and sciences 51: 1371-1379, 2006.
149. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, Ruschoff J and Henkel T: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797-805, 2008.
150. Peng D, Sheta EA, Powell SM, Moskaluk CA, Washington K, Goldknopf IL and El-Rifai W: Alterations in Barrett's-related adenocarcinomas: a proteomic approach. International journal of cancer Journal international du cancer 122: 1303-1310, 2008.
151. Agarwala AK, Hanna N, McCollum A, Bechar N, DiMaio M, Yu M, Tong Y, Becerra CR and Choy H: Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern. ASCO Meeting Abstracts 27: 4557, 2009.
152. Ma HY, Newman E, Ryan T, Miller G, Sarpel U, Pachter HL, Cohen DJ, Choi H, Goldberg JD and Hochster HS: Neoadjuvant therapy of gastric cancer with cetuximab added to both irinotecan and cisplatin, followed by surgical resection and adjuvant chemoradiation. ASCO Meeting Abstracts 27 : e15552, 2009.
153. Tebbutt NC, Parry MM, Zannino D, Strickland AH, Van Hazel GA, Pavlakis N, Ganju V, Mellor D, Dobrovic A and Gebski VJ: Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. British journal of cancer 108: 771-774, 2013.
154. Shi M, Ji J, Wu J, Ma T, Liu Y, Zhou CF, Su Y, Ye ZB, Zhang J and Zhu ZG: Cetuximab Combined With FOLFOX4 as the First-Line Treatment for Advanced Gastric Cancer: Report of 25 Cases from a Single Institution. Hepato-gastroenterology 592012.
155. Wöll E, Greil R, Eisterer W, BechterO, Fridrik MA, Grünberger B, Zabernigg A, Mayrbäurl B, Russ G, Dlaska M, Obrist P and Thaler J: Oxaliplatin, Irinotecan and Cetuximab in Advanced Gastric Cancer. A Multicenter Phase II Trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT). Anticancer Research 31: 4439-4443, 2011.
156. Zhang X, Xu J, Shen L, Wang J, Liang J, Xu N, Bai Y and Wang J: A phase II study of cetuximab (Cetuximab) with cisplatin and capecitabine (Xeloda) as 1st line treatment in advanced gastric cancer. ASCO Meeting Abstracts 26: 15663, 2008.
157. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J and Kang YK: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
158. Koeda K, Sugimoto N, Tanaka J, Tsuda M, Okamoto W, Okuda H, Imamura H, Matsuyama J, Shimokawa T, Sakai D, Fukushima N, Kurokawa Y, Komatsu Y, Tsujinaka T and Furukawa H: A phase ll study of new combination regimen with trastuzumab, S-1, and CDDP in HER2-positive advanced gastric cancer (HERBIS-1). ASCO Meeting Abstracts 31: 4072, 2013.
159. Iwasa S, Nishikawa K, Miki A, Noshiro H, Tsuburaya A, Nishida Y, Miwa H, Masuishi T, Yoshida K, Kodera Y, Boku N, Yamada Y, Morita S, Sakamoto J, Saji S and Kitagawa Y: Multicenter, phase II study of trastuzumab and paclitaxel to treat HER2-positive, metastatic gastric cancer patients naive to trastuzumab (JFMC45-1102). ASCO Meeting Abstracts 31: 4096, 2013.
160. Tew W SM, Schwartz G et al: Phase II trial of erlotinib for second-line treatment in advanced esophageal cancer. Proc Am Soc Clin Oncol GI Cancers Symposium 23: 25a., 2005.
161. Javle M, Pande A, Iyer R, Yang G, LeVea C, Wilding G, Black J, Nava H and Nwogu C: Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. American journal of clinical oncology 31: 329- 334, 2008.
162. Sunpaweravong P, Sunpaweravong S, Sangthawan D, Puttawibul P and Mitarnun W: Combination of gefitinib, cisplatin and 5-FU chemotherapy, and radiation therapy (RT) in newly-diagnosed patients with esophageal carcinoma. ASCO Meeting Abstracts 25: 4605, 2007.
163. Doi T KS, Siena S et al: Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 22: (abstr 1036), 2003.
164. Ferry DR, Anderson M, Beddard K, Tomlinson S, Atherfold P, Obszynska J, Harrison R and Jankowski J: A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response. Clinical Cancer Research 13: 5869-5875, 2007.
165. Zhai Y, Hui Z, Wang J, Zou S, Liang J, Wang X, Lv J, Chen B, Zhu H and Wang L: Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study. Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus/ISDE 2012.
166. Hecht J: Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analyses [abstract]. Proceedings ASCO 2008 Gastrointestinal Cancers Symposium: a43, 2008.